Smruthi Organics Limited was incorporated in July, 1989 as a Private Limited Company and was subsequently converted into a Public Limited Company in February, 1995. The Company was promoted by E Purushotham and Shankarrao R Myakal. The Company is a manufacturer of Active Pharmaceutical Ingredient (API) products in the Anti - Diabetic, Anti - Hypertension and Anti - Infectives Therapeutic categories catering to both the Indian domestic as well as rest of the world (ROW) markets, with clients spanning across Asia, Americas, and Africa. It has 2 manufacturing facilities in Solapur, India.
The Company set up a plant at Solapur, Maharashtra, to manufacture bulk drugs like diloxanide furoate (inst. cap. : 24 tpa) and sulphadiazine (inst. cap. : 36 tpa). It expanded its activities and product range in 1993-94 by manufacturing metronidazole benzoate, tinidazole, paracetamol and norfloxacin.
The company exports furoic acid to the UK market. In 1995, it proposed to expand its product range and set up an additional plant at Chincholi, Maharashtra, for the manufacture of additional bulk drugs like ciprofloxacin and ranitidine HCl. The company issued shares to the public in Dec.`95, to part-finance the project.
In 2011-12, the Company`s expansion project became commercialized from 21st September 2012. In 2021-22, the Company`s Finished Dosage Formulations (FDF) Division was operational fully from April 2021.
In FY 2022-23, the Company launched two new brands, `ENERLIN` and `SOLSITA`, launched another two brands: TRANVIA P and YAMONT LC in pain relief and anti-histamine segments respectively in 2023-24.
Smruthi Organics share price as on 02 Mar 2026 is Rs. 112.9. Over the past 6 months, the Smruthi Organics share price has decreased by 3.01% and in the last one year, it has increased by 4.39%. The 52-week low for Smruthi Organics share price was Rs. 103 and 52-week high was Rs. 164.
Smruthi Organics Limited was incorporated in July, 1989 as a Private Limited Company and was subsequently converted into a Public Limited Company in February, 1995. The Company was promoted by E Purushotham and Shankarrao R Myakal. The Company is a manufacturer of Active Pharmaceutical Ingredient (API) products in the Anti - Diabetic, Anti - Hypertension and Anti - Infectives Therapeutic categories catering to both the Indian domestic as well as rest of the world (ROW) markets, with clients spanning across Asia, Americas, and Africa. It has 2 manufacturing facilities in Solapur, India.
The Company set up a plant at Solapur, Maharashtra, to manufacture bulk drugs like diloxanide furoate (inst. cap. : 24 tpa) and sulphadiazine (inst. cap. : 36 tpa). It expanded its activities and product range in 1993-94 by manufacturing metronidazole benzoate, tinidazole, paracetamol and norfloxacin.
The company exports furoic acid to the UK market. In 1995, it proposed to expand its product range and set up an additional plant at Chincholi, Maharashtra, for the manufacture of additional bulk drugs like ciprofloxacin and ranitidine HCl. The company issued shares to the public in Dec.`95, to part-finance the project.
In 2011-12, the Company`s expansion project became commercialized from 21st September 2012. In 2021-22, the Company`s Finished Dosage Formulations (FDF) Division was operational fully from April 2021.
In FY 2022-23, the Company launched two new brands, `ENERLIN` and `SOLSITA`, launched another two brands: TRANVIA P and YAMONT LC in pain relief and anti-histamine segments respectively in 2023-24.
Smruthi Organics share price as on 02 Mar 2026 is Rs. 112.9. Over the past 6 months, the Smruthi Organics share price has decreased by 3.01% and in the last one year, it has increased by 4.39%. The 52-week low for Smruthi Organics share price was Rs. 103 and 52-week high was Rs. 164.
